Novel hormonal therapy for castration-resistant prostate cancer

被引：8

作者：

Sternberg, C. N. ^{[1
]}

机构：

[1] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

abiraterone; enzalutamide; hormone therapy; prostate cancer; ACETATE PLUS PREDNISONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTITUMOR-ACTIVITY; KETOCONAZOLE; ANTIANDROGEN; DOCETAXEL; CYP17; INHIBITION; SURVIVAL;

D O I：

10.1093/annonc/mds362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：259 / 263

页数：5

共 30 条

[21]

Scher H, 2012, P ANN M AM SOC CL S5, V30

[22]

Scher H.I., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, DOI DOI 10.1056/NEJMOA1207506

[23]

Scher HI, 2011, P ANN M AM SOC CLI S

[24] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group [J].

Scher, Howard I. ;

Halabi, Susan ;

Tannock, Ian ;

Morris, Michael ;

Sternberg, Cora N. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Higano, Celestia ;

Bubley, Glenn J. ;

Dreicer, Robert ;

Petrylak, Daniel ;

Kantoff, Philip ;

Basch, Ethan ;

Kelly, William Kevin ;

Figg, William D. ;

Small, Eric J. ;

Beer, Tomasz M. ;

Wilding, George ;

Martin, Alison ;

Hussain, Maha .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1148-1159

[25] Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study [J].

Scher, Howard I. ;

Beer, Tomasz M. ;

Higano, Celestia S. ;

Anand, Aseem ;

Taplin, Mary-Ellen ;

Efstathiou, Eleni ;

Rathkopf, Dana ;

Shelkey, Julia ;

Yu, Evan Y. ;

Alumkal, Joshi ;

Hung, David ;

Hirmand, Mohammad ;

Seely, Lynn ;

Morris, Michael J. ;

Danila, Daniel C. ;

Humm, John ;

Larson, Steve ;

Fleisher, Martin ;

Sawyers, Charles L. .

LANCET, 2010, 375 (9724) :1437-1446

[26]

Siegel R, 2012, CA CANC J CLIN, V61

[27] Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583) [J].

Small, EJ ;

Halabi, S ;

Dawson, NA ;

Stadler, WM ;

Rini, BI ;

Picus, J ;

Gable, P ;

Torti, FM ;

Kaplan, E ;

Vogelzang, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1025-1033

[28] A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial [J].

Small, Eric Jay ;

Weinberg, Vivian K. ;

Ryan, Charles J. ;

Higano, Celestia S. ;

Lin, Amy Mimi ;

Maruca, Yvonne ;

Alumkal, Joshi J. ;

Yu, Evan Y. ;

Rosenberg, Jonathan E. ;

Beer, Tomasz M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)

[29] Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer [J].

Tran, Chris ;

Ouk, Samedy ;

Clegg, Nicola J. ;

Chen, Yu ;

Watson, Philip A. ;

Arora, Vivek ;

Wongvipat, John ;

Smith-Jones, Peter M. ;

Yoo, Dongwon ;

Kwon, Andrew ;

Wasielewska, Teresa ;

Welsbie, Derek ;

Chen, Charlie Degui ;

Higano, Celestia S. ;

Beer, Tomasz M. ;

Hung, David T. ;

Scher, Howard I. ;

Jung, Michael E. ;

Sawyers, Charles L. .

SCIENCE, 2009, 324 (5928) :787-790

[30] Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor [J].

Watson, Philip A. ;

Chen, Yinan F. ;

Balbas, Minna D. ;

Wongvipat, John ;

Socci, Nicholas D. ;

Viale, Agnes ;

Kim, Kwanghee ;

Sawyers, Charles L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (39) :16759-16765

← 1 2 3 →